Management and investigation of neonatal encephalopathy: 2017 update

TLDR

Neonatal encephalopathy arises from multiple causes beyond hypoxic‑ischaemia, and optimal care may need tailoring to gender, genetics, injury severity, and inflammation. This review outlines a diagnostic approach and current evidence on resuscitation and management of hypoxic‑ischaemic encephalopathy, and proposes evaluating adjunct therapies to enhance hypothermic neuroprotection in future trials. Diagnosis relies on careful history, examination, and targeted investigations, while recent research emphasizes optimal resuscitation practices such as delayed cord clamping after ventilation and air resuscitation. Routine therapeutic hypothermia has reduced morbidity in moderate‑to‑severe HIE (NNT = 7), 25 % of infants with 10‑min asystole who are cooled achieve normal outcomes—highlighting the need for individualized resuscitation decisions—and 72‑hour cooling at 33.5 °C maximizes benefit, whereas deeper or longer cooling worsens outcomes.

Abstract

This review discusses an approach to determining the cause of neonatal encephalopathy, as well as current evidence on resuscitation and subsequent management of hypoxic-ischaemic encephalopathy (HIE). Encephalopathy in neonates can be due to varied aetiologies in addition to hypoxic-ischaemia. A combination of careful history, examination and the judicious use of investigations can help determine the cause. Over the last 7 years, infants with moderate to severe HIE have benefited from the introduction of routine therapeutic hypothermia; the number needed to treat for an additional beneficial outcome is 7 (95% CI 5 to 10). More recent research has focused on optimal resuscitation practices for babies with cardiorespiratory depression, such as delayed cord clamping after establishment of ventilation and resuscitation in air. Around a quarter of infants with asystole at 10 min after birth who are subsequently cooled have normal outcomes, suggesting that individualised decision making on stopping resuscitation is needed, based on access to intensive treatment unit and early cooling. The full benefit of cooling appears to have been exploited in our current treatment protocols of 72 hours at 33.5°C; deeper and longer cooling showed adverse outcome. The challenge over the next 5–10 years will be to assess which adjunct therapies are safe and optimise hypothermic brain protection in phase I and phase II trials. Optimal care may require tailoring treatments according to gender, genetic risk, injury severity and inflammatory status.